Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1674 1699
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17161929 | CHO CELL EXPRESSED HET IL-15 | Non-Final OA | NOVARTIS AG |
| 17708660 | METHODS FOR TREATING IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNOSUPPRESSION | Final Rejection | Novo Nordisk A/S |
| 17741095 | DESIGNED IL-2 VARIANTS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 19254656 | CYTOKINE COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Zahav Bioscience LLC |
| 17920942 | CD25-TARGETED IL-2 FOR INCREASING CD4 T CELL FORMATION AND TREATMENT OF INFECTIONS | Final Rejection | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. |
| 17924066 | MODULATION OF MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN SIGNALING | Non-Final OA | EBERHARD KARLS UNIVERSITÄT TÜBINGEN |
| 18838513 | MASKED IL12 PROTEIN | Final Rejection | Tagworks Pharmaceuticals B.V. |
| 18035249 | USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS | Non-Final OA | ethris GmbH |
| 18351442 | COMPOSITIONS AND METHODS FOR SELECTIVE ELIMINATION AND REPLACEMENT OF HEMATOPOIETIC STEM CELLS | Non-Final OA | Poseida Therapeutics, Inc. |
| 18259309 | METHODS USING ANTI-SLC3A2 AUTOANTIBODIES AND SLC3A2 FOR DETECTION OF GLIOMA BRAIN TUMOR FROM PATIENT SERUM | Non-Final OA | Istanbul Üniversitesi |
| 18312245 | ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF | Final Rejection | Werewolf Therapeutics, Inc. |
| 17961397 | MULTI-LIGAND DRUG CONJUGATES AND USES THEREOF | Non-Final OA | COHERENT BIOPHARMA I, LIMITED |
| 17935690 | DEGRADER-ANTIBODY CONJUGATES AND METHODS OF USING SAME | Non-Final OA | Anglex, Inc. |
| 17819254 | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA | Non-Final OA | EIT Pharma, Inc. |
| 17760279 | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA | Non-Final OA | EIT Pharma, Inc. |
| 17555483 | Polypeptides in Preparation of Drugs for Treatment or Prevention of Rheumatoid Arthritis | Non-Final OA | Hanmei XU |
| 16356483 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS | Final Rejection | In3Bio Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy